Table 1.
Characteristics of studies included in meta-analyses.
| Study & year | Country | Follow-up (mo) | Sample size | Mean Age (yr) |
Male (%) |
Disease subtype |
End-point | Quality (NOS) |
|---|---|---|---|---|---|---|---|---|
| Cetin M 2016[13] | Turkey | 31.6 | 2661 | 59.8 | 66.4 | ACS | Long term MACEs Long term mortality In-hospital MACEs |
7 |
| Karata M 2016[14] | Turkey | 12.0 | 513 | 56.4 | 71.8 | STEMI | Long term MACEs Long term mortality |
7 |
| Wu T 2019[15] | China | 60.0 | 673 | 59.1 | 80.7 | CAD | Long term mortality Long term MACEs |
7 |
| Acikgoz S 2016[16] | Turkey | 23.4 | 1598 | 55.9 | 83.9 | STEMI | Long term mortality In-hospital mortality |
9 |
| Zhang Y 2016[17] | China | 24.6 | 3630 | 57.9 | 70.4 | ACS | Long term MACEs | 7 |
| Chen L 2021[18] | China | 12.0 | 1405 | 64.6 | 69.2 | ACS | Long term MACEs In-hospital MACEs |
8 |
| Hu J 2018[19] | China | 6.0 | 278 | 58.6 | 67.4 | STEMI | Long term MACEs | 7 |
| Mao Q 2019[20] | China | 12.0 | 435 | 63.0 | 67.4 | ACS | Long term MACEs | 7 |
| Oylumlu M 2020[21] | Turkey | 39.0 | 825 | 62.4 | 71.3 | ACS | Long-term mortality | 7 |
ACS = Acute coronary syndrome, CAD = coronary artery disease, MACEs = Major adverse cardiac events, NOS = New Caslte-Ottawa scale, STEMI = ST-segment elevation myocardial infarction.